TAL Education Group header image

TAL Education Group

TAL

Equity

ISIN null / Valor 11869921

New York Stock Exchange, Inc (2026-05-01)
USD 11.17+0.45%

TAL Education Group
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

TAL Education Group is a Beijing‑based provider of K–12 educational services in China, operating both a network of physical learning centers and online platforms that deliver instruction in core academic subjects (notably Chinese, mathematics and English), test preparation and supplemental programs; it also develops curricula, digital learning tools and teacher-training services and earns revenue from tuition, subscriptions and educational materials. The company combines classroom instruction with live and recorded online classes and has invested in adaptive learning and other education technologies to support personalized learning and content distribution. As one of the larger players in China’s after‑school tutoring market, TAL has been reshaping its business mix and expanding technology and non‑core offerings in response to recent regulatory reforms affecting private K–12 tutoring.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (05.04.2026):

TAL Education Group — third quarter of fiscal year 2026 (three months ended November 30, 2025): TAL reported strong top-line and profit recovery in Q3 FY2026 with net revenues of US$770.2 million (up 27.0% year-over-year), GAAP net income attributable to TAL of US$130.6 million (vs. US$23.1 million a year earlier) and GAAP income from operations of US$93.1 million (compared with a loss from operations in the prior-year quarter). Non‑GAAP results (excluding share‑based compensation) also improved materially. The company finished the quarter with healthy operating cash generation and ample liquidity.

Revenue growth

Net revenues for Q3 FY2026 were US$770.2 million, a 27.0% increase versus Q3 FY2025. For the first nine months of FY2026, revenues were US$2,206.5 million, up 34.5% year‑over‑year.

Profitability turnaround

GAAP income from operations was US$93.1 million in Q3 FY2026 (vs. a US$17.4 million loss in Q3 FY2025). GAAP net income attributable to TAL was US$130.6 million in Q3 (vs. US$23.1 million). Non‑GAAP income from operations was US$104.0 million and non‑GAAP net income attributable to TAL was US$141.4 million for the quarter (both exclude share‑based compensation).

Margins and gross profit

Gross profit rose to US$431.8 million in Q3 FY2026 (up 35.0% YoY) and gross margin improved to 56.1% from 52.7% a year earlier, indicating better revenue mix and scale benefits.

Operating costs and share‑based compensation

Operating costs and expenses were US$677.0 million in Q3 (an 8.5% increase YoY). Total share‑based compensation allocated to operating expenses declined ~30.2% QoQ to US$10.8 million in the quarter; non‑GAAP operating costs (ex‑share‑based comp) were US$666.2 million.

Cash, liquidity and cash flow

Cash, cash equivalents and short‑term investments totaled US$3,617.4 million as of November 30, 2025 (roughly flat versus Feb 28, 2025). Net cash provided by operating activities in Q3 was strong at US$526.7 million (US$816.4 million for the first nine months).

Deferred revenue and balance sheet trends

Deferred revenue rose materially to US$1,162.8 million as of November 30, 2025 (from US$671.2 million at Feb 28, 2025), supporting future revenue visibility. Total assets increased to US$5,919.6 million and accumulated deficit narrowed to US$(334.5) million.

Per‑ADS earnings and non‑GAAP metrics

Basic and diluted net income per ADS in Q3 were US$0.24 and US$0.23, respectively. Non‑GAAP basic and diluted net income per ADS were both US$0.25 (three ADSs represent one Class A common share).

Capital return and share buyback

Board authorized a new share repurchase program of up to US$600 million (announced July 28, 2025). Through Jan 28, 2026 the company repurchased 844,856 common shares for approximately US$27.7 million.

Summarized from source with an LLMView Source

Key figures

27.9%1Y
94.3%3Y
-80.4%5Y

Performance

52.3%1Y
59.2%3Y
97.7%5Y

Volatility

Market cap

5148 M

Market cap (USD)

Daily traded volume (Shares)

2,173,641

Daily traded volume (Shares)

1 day high/low

9.735 / 9.5

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc Amphastar Pharmaceuticals Inc Valor: 24511852
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.36%USD 21.88
Schrodinger Inc
Schrodinger Inc Schrodinger Inc Valor: 51947209
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.60%USD 12.39
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.35%USD 2.84
Outset Medical Inc
Outset Medical Inc Outset Medical Inc Valor: 56717137
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.11%USD 4.36
BridgeBio Pharma Inc
BridgeBio Pharma Inc BridgeBio Pharma Inc Valor: 48204826
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.59%USD 68.56
Protagonist Therapeutics Inc
Protagonist Therapeutics Inc Protagonist Therapeutics Inc Valor: 33278818
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.61%USD 98.37
Allogene Therapeutics Inc
Allogene Therapeutics Inc Allogene Therapeutics Inc Valor: 43756548
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.94%USD 2.15
Summit Therapeutics Inc
Summit Therapeutics Inc Summit Therapeutics Inc Valor: 56903013
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-24.91%USD 16.11
Glaukos Corp
Glaukos Corp Glaukos Corp Valor: 28262610
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.40%USD 140.22
Hims & Hers Health Inc
Hims & Hers Health Inc Hims & Hers Health Inc Valor: 59397181
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.88%USD 27.41